ArticleBone marrow transplantation2010
Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group.
Article in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Donor and stem cell source selection in hematopoietic cell transplantation in the Asia-Pacific region: results from the APBMT Activity Survey 2022-2023.Blood cell therapy · 2026Article
- Exploring the financial burden of pediatric bone marrow transplantation: a cross-sectional Study from the caregiver's viewpoint.BMC health services research · 2025Article
- Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021.Blood cell therapy · 2024Article
- Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey.Blood cell therapy · 2023Article
- A Comparison of the Physical Activity and Sedentary Behavior between Autologous and Allogeneic Hematopoietic Stem Cell Transplantation Survivors.Internal medicine (Tokyo, Japan) · 2023Observational
- Alternate Donor Transplantation.Blood cell therapy · 2022Article
- Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT.Blood cell therapy · 2022Article
- The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region.Blood cell therapy · 2021Article
- A review of hematopoietic cell transplantation in China: data and trends during 2008-2016.Bone marrow transplantation · 2017Article
- Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries.International journal of hematology · 2016Article
- Hematopoietic SCT in Iranian children 1991-2012.Bone marrow transplantation · 2015Article
- Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Observational
- Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.Haematologica · 2013Observational
- The EBMT activity survey: 1990-2010.Bone marrow transplantation · 2012Article
- The EBMT activity survey 2009: trends over the past 5 years.Bone marrow transplantation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hematopoietic SCT (HSCT) activity in nine Asian countries/regions was surveyed to overview the current situation. Data of 58 113 HSCTs (allogeneic: 63% vs autologous: 37%) performed between 1986 and 2006 by 432 transplant teams were collected. The number of HSCTs has been increasing in the past two decades in most countries/regions. The increase in allogeneic HSCTs is greater than in autologous HSCTs. The proportion of unrelated donors among allogeneic HSCTs in 2006 varied widely from <1% (Iran and Vietnam) to 62% (Japan). The use of each stem cell source, that is, BM, PBSC, cord blood and others (including co-infusion of BM and PBSC), also varied widely (36, 58, 0.1 and 6% in HSCT from related donors, respectively, and 53, 11, 35 and 1% in HSCT from unrelated donors, respectively). HSCTs have been continuously increasing for all indications except for chronic myelogenous leukemia and solid tumors. Hemoglobinopathy is a common indication among non-malignant diseases in many Asian countries/regions except for China, Japan and Korea. This survey clearly shows the recent progress of HSCTs in Asia and also some differences in donor and stem cell selection and disease application among countries/regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.